DPP4 and COVID-19: Our multivariable Cox regression analysis, adjusted for potential confounders including age, sex, and comorbidities, showed that DPP-4 inhibitor use was independently associated with reduced COVID-19-related mortality (adjusted HR: 0.455; 95% CI: 0.414–0.499).